Enorama Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-57.01	-62.81	-47.52	-42.13	-41.47	-26.94
Depreciation & Amortization	0.42	0.47	20.41	3.55	3.54	1.38
Other Adjustments	-5.5	4.24	3.71	-2.49	-0.56	-0.8
Change in Receivables	13.48	-1.41	0.72	2.26	4.2	-2.6
Changes in Inventories	-0.25	-6.12	-6.98	-1.46	-1.6	0.48
Changes in Accounts Payable	-2.54	6.36	-6.04	-1.09	2.94	-1.68
Operating Cash Flow	-46.09	-59.26	-35.7	-41.35	-32.96	-30.16
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-	0	0	0	0	-0.06
Purchases of Intangible Assets	-	0	0	0	0	-1.76
Investing Cash Flow	-	0	0	0	0	-1.82
Long-Term Debt Issued	37.01	20.13	0	2.2	20	8
Long-Term Debt Repaid	-3.8	0	-0.44	-3.46	-2.09	-9.92
Net Long-Term Debt Issued (Repaid)	33.21	20.13	-0.44	-1.26	17.91	-1.92
Issuance of Common Stock	22.29	31.17	40.4	43.13	9	43.21
Net Common Stock Issued (Repurchased)	22.29	31.17	40.4	43.13	9	43.21
Other Financing Activities	-0.02	-0.61	-4.68	0	-1.57	-1.79
Financing Cash Flow	55.48	50.69	35.29	41.86	25.35	39.51
Effect of Exchange Rate Changes on Cash and Cash Equivalents	3.73	9.52	-3.65	1.5	-0.45	-0.06
Net Cash Flow	9.39	-8.57	-0.42	0.51	-7.61	7.52
Free Cash Flow	-46.09	-59.26	-35.7	-41.35	-32.96	-30.22
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	4558.56%	879.50%	-129.30%	-3688.58%	-349.02%	-233.44%
Free Cash Flow Per Share	-0.64	-0.85	-0.67	-1.49	-4.21	-4.88
Levered Free Cash Flow	-34.44	-54.3	-36.86	-44.87	-19.24	-29.55
Unlevered Free Cash Flow	-59.38	-62.1	-40.13	-41.12	-36.59	-26.82